Gold rally takes a breather amid Gaza ceasefire, Fed minutes
LONDON - Polar Capital Global Healthcare Trust plc has disclosed its top equity holdings and sector exposures as of September 30, 2025, according to a press release statement issued Monday.
The trust’s portfolio shows Eli Lilly & Co as its largest holding at 7.1%, followed by AstraZeneca at 6.1% and Abbott Laboratories at 5.0%. The top ten equity positions collectively represent 41.8% of the portfolio.
In terms of sector allocation, pharmaceuticals lead with a 31.1% exposure, while healthcare equipment and biotechnology follow at 24.2% and 21.1% respectively. The trust maintains a small cash position of 1.9%.
Geographically, the United States dominates the portfolio with 53.2% exposure, with Denmark representing the second-largest country allocation at 13.7%. The United Kingdom accounts for 6.1% of investments, followed by Switzerland at 5.2% and India at 4.6%.
Other notable holdings in the top ten include UCB (3.8%), Genmab A/S (3.6%), Thermo Fisher Scientific (3.4%), Teva Pharmaceutical Industries (3.3%), Sandoz Group AG (3.3%), Exact Sciences Corp (3.2%), and Edwards Lifesciences Corp (3.1%).
The trust’s sector exposures also include healthcare services (5.5%), life sciences tools & services (5.4%), healthcare facilities (5.0%), managed healthcare (3.1%), healthcare distributors (1.6%), and healthcare technology (1.1%).
The company indicated that its monthly factsheet with additional information will be available on its website approximately ten working days after the month-end.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.